Evaluation of the Prevalence of HER-2 Expression and Its Relationship with Prognostic Parameters in Colorectal Carcinoma

Işık, Cansu Benli; Barut, Saime Gül

doi:10.4274/imj.galenos.2020.56563

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Kamal and Jalal 33 , in 2019, HER2 overexpression was found in 53.4% of CRC patients and showed a significant association with the grade of the tumor but no association with age, sex, or tumor site. In a study by Işik and Barut 34 , in 2020 on 123 CRC patients, HER2 overexpression was found in 13% of patients, and HER2 overexpression showed a significant association with distant metastasis ( P <0.05) and showed no relationship with age, sex, tumor site, or grade of the tumor. In a study by Kaur et al .…”

Section: Discussionmentioning

confidence: 94%

Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study

Rudiman

Wijaya

Soedjana

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background: In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colorectal cancer patients diagnosed after metastases, some patients will develop metastases after undergoing surgical resection of the primary tumor. The survival of metastatic colorectal cancer patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti–epidermal growth factor receptor (EGFR), and anti–human epidermal growth factor receptor-2 (HER2). This study aims to assess the relationship between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and HER2 expression for targeted therapy implementation. Patients and methods: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the digestive surgery division. There were 58 study subjects. Examination of KRAS mutations was carried out by PCR on fresh tumor tissue obtained from surgery or colonoscopy. Meanwhile, the HER2 examination used the immunohistochemistry method of paraffin blocks for anatomical pathology examination. Results: Examination of KRAS mutations showed 28/58 (43.8%) patients with colorectal cancer, while HER2 overexpression was found in 6/58 (10.3%) patients with colorectal cancer. Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). Conclusion: There is no association between KRAS mutations and HER2 overexpression in colorectal cancer patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study

Rudiman

Wijaya

Soedjana

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…Human epidermal growth factor receptor 2 (ErbB2, HER2, or neu) is overexpressed on the cellular surface of tumors (Roy et al, 2019;Işık and Barut, 2020;Egebjerg et al, 2021;Omranipour et al, 2021), especially in breast (Oh and Bang, 2020) and gasteric (Boku, 2014) cancers. From a structural perspective, ErbB2 is formed by three main domains: an extracellular domain consisting of four subdomains I, II, III, and IV, a membraneembedded region, and an intercellular domain with tyrosine kinase activity (Cho et al, 2003) (Figure 1B).…”

Section: Introductionmentioning

confidence: 99%

Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin

Moghaddam

Maroufi²,

Zareei³

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Although the anti-cancer activity of ricin is well-known, its non-specific targeting challenges the development of ricin-derived medicines. In the present study, novel potential ribosome-inactivating fusion proteins (RIPs) were computationally engineered by incorporation of an ErbB2-dependant penetrating peptide (KCCYSL, MARAKE, WYSWLL, MARSGL, MSRTMS, and WYAWML), a linker (either EAAAK or GGGGS) and chain A of ricin which is responsible for the ribosome inactivation. Molecular dynamics simulations assisted in making sure that the least change is made in conformation and dynamic behavior of ricin chain A in selected chimeric protein (CP). Moreover, the potential affinity of the selected CPs against the ligand-uptaking ErbB2 domain was explored by molecular docking. The results showed that two CPs (CP2 and 10) could bind the receptor with the greatest affinity.

show abstract

Evaluation of the Prevalence of HER-2 Expression and Its Relationship with Prognostic Parameters in Colorectal Carcinoma

Cited by 2 publications

References 0 publications

Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study

Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study

Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin

Contact Info

Product

Resources

About